MXPA03010747A - Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. - Google Patents

Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.

Info

Publication number
MXPA03010747A
MXPA03010747A MXPA03010747A MXPA03010747A MXPA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A
Authority
MX
Mexico
Prior art keywords
antibodies
immunospecifically bind
relates
methods
trail receptors
Prior art date
Application number
MXPA03010747A
Other languages
English (en)
Inventor
A Rosen Craig
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03010747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MXPA03010747A publication Critical patent/MXPA03010747A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a anticuerpos y moleculas relacionadas que se unen inmunoespecificamente a receptor de TRAIL, TR4; dichos anticuerpos tienen usos, por ejemplo, en la prevencion y tratamiento de canceres y otros trastornos proliferativos; la invencion tambien se refiere a moleculas de acido nucleico que codifican anticuerpos anti-TR4, vectores y celulas hospedero que contienen estos acidos nucleicos, y metodos para producir los mismos; la presente invencion se refiere a metodos y composiciones para prevenir, detectar, diagnosticar, tratar o aliviar una enfermedad o trastorno, especialmente cancer y otros trastornos hiperproliferativos, que comprende administrar a un animal, preferiblemente a un humano, una cantidad efectiva de uno o mas anticuerpos o fragmentos o variantes de los mismos, o moleculas relacionadas, que se unen inmunoespecificamente al receptor de TRAIL, TR4.
MXPA03010747A 2001-05-25 2002-05-07 Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. MXPA03010747A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US29347301P 2001-05-25 2001-05-25
US29498101P 2001-06-04 2001-06-04
US30917601P 2001-08-02 2001-08-02
US32380701P 2001-09-21 2001-09-21
US32736401P 2001-10-09 2001-10-09
US33104401P 2001-11-07 2001-11-07
US33131001P 2001-11-14 2001-11-14
US34123701P 2001-12-20 2001-12-20
US36986002P 2002-04-05 2002-04-05
PCT/US2002/014268 WO2002097033A2 (en) 2001-05-25 2002-05-07 Antibodies that immunospecifically bind to trail receptors

Publications (1)

Publication Number Publication Date
MXPA03010747A true MXPA03010747A (es) 2004-03-02

Family

ID=50151047

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010747A MXPA03010747A (es) 2001-05-25 2002-05-07 Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.

Country Status (14)

Country Link
US (1) US7064189B2 (es)
EP (1) EP1572874B1 (es)
JP (2) JP4309758B2 (es)
KR (1) KR100942393B1 (es)
CN (1) CN100594935C (es)
AU (1) AU2002309647C1 (es)
CA (1) CA2446723C (es)
DK (1) DK1572874T3 (es)
ES (1) ES2437992T3 (es)
HK (1) HK1075470A1 (es)
MX (1) MXPA03010747A (es)
NZ (1) NZ529359A (es)
PT (1) PT1572874E (es)
WO (1) WO2002097033A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
WO2002097033A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2192130A1 (en) 2001-07-03 2010-06-02 Genentech, Inc. Human DR4 antibodies and uses thereof
JP2005516958A (ja) * 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
EP1506237A1 (en) * 2002-05-17 2005-02-16 Fusion Antibodies Limited Treatment of cancer by the use of anti fas antibody
EP1534336A4 (en) * 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
PT1606318E (pt) * 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
DE602004030898D1 (de) * 2003-04-16 2011-02-17 Tasuku Honjo Screening-verfahren für heilmittel gegen herzkrankheit und medizinische zusammensetzung zur behandlung von herzkrankheit
EP1633316A4 (en) * 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
JP5237638B2 (ja) 2004-08-06 2013-07-17 ジェネンテック， インコーポレイテッド バイオマーカーを用いたアッセイおよび方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
ATE533058T1 (de) 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
US7776605B2 (en) * 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
CA2667012A1 (en) * 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
WO2010111842A1 (zh) * 2009-04-03 2010-10-07 中国医学科学院基础医学研究所 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
EP2970473B1 (en) 2013-03-14 2017-08-16 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
WO2016074245A1 (en) * 2014-11-14 2016-05-19 Beijing Cotimes Biotech Company Limited Trail receptor-binding agents and uses of same
MA43365A (fr) * 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
JP2022512591A (ja) * 2018-10-05 2022-02-07 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4496654A (en) * 1983-04-08 1985-01-29 Quidel Detection of HCG with solid phase support having avidin coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60150456A (ja) 1984-01-19 1985-08-08 Diesel Kiki Co Ltd 内燃機関用燃料噴射装置
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
NZ229700A (en) 1988-06-24 1993-01-27 Dow Chemical Co Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
FI90454C (fi) 1990-02-22 1994-02-10 Patenttitoimisto T Poutanen Oy Menetelmä naulalevykattotuolin valmistamiseksi
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE4025687A1 (de) 1990-08-14 1992-02-20 Ruetgerswerke Ag Durch strahlung vernetzbare bindemittelgemische
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
CA2095836C (en) 1990-11-09 1999-04-06 Stephen D. Gillies Cytokine immunoconjugates
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2096749T3 (es) 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
US5714711A (en) 1990-12-31 1998-02-03 Mei Corporation Encapsulated propellant grain composition, method of preparation, article fabricated therefrom and method of fabrication
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2067031C (en) 1991-04-26 2003-02-18 Shigekazu Nagata Dna coding for human cell surface antigen
ATE199647T1 (de) 1991-05-14 2001-03-15 Univ Connecticut Gerichtete abgabe von genen, die immunogene proteine kodieren
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4119353C1 (es) 1991-06-12 1992-12-17 Deutsche Rockwool Mineralwoll Gmbh, 4390 Gladbeck, De
US5356603A (en) 1991-06-17 1994-10-18 Johnson Matthey Inc. Method for the production of hydrocyanic acid using a corrugated catalyst
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE4233586A1 (de) 1992-10-06 1994-04-07 Bayer Ag 3-Imino-3-alkoxy-propionsäurelactate und deren tautomere Acrylsäurelactate
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
NZ257942A (en) 1992-10-23 1996-04-26 Immunex Corp Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
NZ275711A (en) 1993-10-14 1998-03-25 Immunex Corp Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
JP2552425B2 (ja) 1993-12-14 1996-11-13 コナミ株式会社 実況中継機能付きゲーム機
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
DE69434988T2 (de) 1994-11-07 2008-03-06 Human Genome Sciences, Inc. Tumornekrose-faktor-gamma
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP3521016B2 (ja) 1995-03-27 2004-04-19 松下電器産業株式会社 直交周波数分割多重信号の受信方法および受信装置
US5516717A (en) 1995-04-19 1996-05-14 United Microelectronics Corporation Method for manufacturing electrostatic discharge devices
EP0822984A4 (en) 1995-04-27 2000-05-03 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTORS IN MEN
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996035735A1 (en) 1995-05-08 1996-11-14 Hourani Michel J Alkoxylated dimethylolpropionic acid modifier
DE19523218A1 (de) 1995-06-27 1997-01-02 Schaeffler Waelzlager Kg Hydraulisch betätigte Ausrückvorrichtung für eine Reibungskupplung
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
DE19611367A1 (de) 1996-03-22 1997-09-25 Bayer Ag Verfahren zur Herstellung Kohlenwasserstoff-getriebener Polyurethan-Hartschaumstoffe
JP2000508522A (ja) 1996-03-22 2000-07-11 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド アポトーシス誘導分子ｉｉ
WO1997035904A1 (en) 1996-03-27 1997-10-02 Novartis Ag Process for manufacture of a porous polymer from a mixture
EP0920505B1 (en) 1996-08-16 2008-06-04 Schering Corporation Mammalian cell surface antigens; related reagents
EP2025682A3 (en) 1996-08-16 2009-06-17 Human Genome Sciences, Inc. Human endokine alpha
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
WO1998012344A1 (en) 1996-09-18 1998-03-26 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6395276B1 (en) 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
EP0857782A3 (en) 1997-01-27 1999-12-22 Smithkline Beecham Corporation Novel mammalian DD-1 gene
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
CA2221687A1 (en) 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CA2644454A1 (en) 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
JP2002512515A (ja) 1997-04-16 2002-04-23 ミレニアム ファーマシューティカルズ インク． 腫瘍壊死因子受容体関連蛋白質ＴＡＮＧＯ−６３ｄおよびＴＡＮＧＯ−６３ｅ
WO1998049305A1 (en) 1997-05-01 1998-11-05 Amgen Inc. Chimeric opg polypeptides
DK1860187T3 (da) * 1997-05-15 2011-10-31 Genentech Inc Apo-2-receptor
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
CA2292790A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
AU7830398A (en) 1997-06-11 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
EP1032661A1 (en) 1997-06-18 2000-09-06 Genentech, Inc. Apo-2DcR
EP1001990A4 (en) 1997-06-26 2001-12-19 Immunex Corp PROTEIN BINDING TO TRAIL PROTEIN
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
AU8395798A (en) 1997-07-15 1999-02-10 Immunex Corporation Trail receptor
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
DK1009817T3 (da) 1997-08-26 2010-01-18 Genentech Inc RTD-receptor
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP4357738B2 (ja) 1997-09-12 2009-11-04 アポテック エール エ デ− エス．アー． システインリッチなレセプターであるｔｒａｉｎ
KR20010031713A (ko) 1997-11-03 2001-04-16 벤슨 로버트 에이치. 맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
WO2000008155A2 (en) 1998-08-07 2000-02-17 Incyte Pharmaceuticals, Inc. Human receptor-associated proteins
WO2000021554A1 (fr) 1998-10-09 2000-04-20 Sankyo Company, Limited Prevention et traitement de la cachexie
DE19856878A1 (de) 1998-12-10 2000-06-15 Inst Polymerforschung Dresden Härtbare uretdiongruppenhaltige Massen und ein Verfahren zu ihrer Herstellung und Verarbeitung sowie ihre Verwendung
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
AU3881100A (en) 1999-03-15 2000-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
AU4817200A (en) 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
CA2373063A1 (en) 1999-05-06 2000-11-16 Jian Ni Death domain containing receptor 4
WO2000071150A1 (en) 1999-05-20 2000-11-30 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
AU5166200A (en) 1999-05-28 2000-12-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
DE60042066D1 (de) 1999-05-28 2009-06-04 Genentech Inc Chimärische dr4 antikörper und ihre verwendung
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
AU6343400A (en) 1999-07-09 2001-01-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2002097033A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
ES2437992T3 (es) 2014-01-15
PT1572874E (pt) 2013-12-11
KR100942393B1 (ko) 2010-02-17
CA2446723C (en) 2014-01-21
AU2002309647C1 (en) 2008-09-11
US7064189B2 (en) 2006-06-20
WO2002097033A2 (en) 2002-12-05
EP1572874B1 (en) 2013-09-18
EP1572874A2 (en) 2005-09-14
DK1572874T3 (da) 2013-12-16
AU2002309647B2 (en) 2008-01-24
EP1572874A4 (en) 2006-05-31
JP4309758B2 (ja) 2009-08-05
WO2002097033A3 (en) 2005-10-20
CA2446723A1 (en) 2002-12-05
CN100594935C (zh) 2010-03-24
US20030190685A1 (en) 2003-10-09
JP2005515963A (ja) 2005-06-02
JP2009062393A (ja) 2009-03-26
CN1635908A (zh) 2005-07-06
HK1075470A1 (en) 2005-12-16
KR20040003015A (ko) 2004-01-07
NZ529359A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
MXPA03010747A (es) Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
DE60028970D1 (de) An her2 bindende peptidverbindungen
EP1401870A4 (en) ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
BE2012C005I2 (es)
WO2001055448A8 (en) Nucleic acids, proteins, and antibodies
WO2004013287A3 (en) Antibodies against c3a receptor
WO2001059063A3 (en) Nucleic acids, proteins, and antibodies
WO2003089575A3 (en) Antibodies that specifically bind to tl5
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003085093A3 (en) Antibodies that specifically bind to gmad
WO2004003144A3 (en) Antibodies that specifically bind to reg iv
MXPA03003902A (es) Polipeptidos de proquineticina, composiciones relacionadas y metodos.
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
WO2004016753A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
ATE518884T1 (de) Spezifisch an chemokin beta-4 bindende antikörper
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2003086301A3 (en) Antibodies that specifically bind to tr2
WO2005018536A3 (en) Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
CY1114921T1 (el) Αντισωματα που δεσμευονται ανοσοειδικα στους trail υποδοχεις
WO2001055313A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
FG Grant or registration